S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

QIAGEN Stock Forecast, Price & News

+1.20 (+2.24%)
(As of 12/8/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
919,915 shs
Average Volume
805,701 shs
Market Capitalization
$12.48 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QIAGEN and its competitors with MarketBeat's FREE daily newsletter.



QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.


QIAGEN (NYSE:QGEN) Shares Gap Down to $56.47
November 29, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Year Founded

Sales & Book Value

Annual Sales
$1.87 billion
Cash Flow
$3.30 per share
Book Value
$13.22 per share


Net Income
$359.19 million
Pretax Margin




Free Float
Market Cap
$12.48 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.38 out of 5 stars

Medical Sector

1127th out of 1,394 stocks

Biological Products, Except Diagnostic Industry

172nd out of 202 stocks

Analyst Opinion: 1.3Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

QIAGEN (NYSE:QGEN) Frequently Asked Questions

Is QIAGEN a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for QIAGEN in the last year. There are currently 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" QIAGEN stock.
View analyst ratings for QIAGEN
or view top-rated stocks.

How has QIAGEN's stock price been impacted by Coronavirus?

QIAGEN's stock was trading at $41.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, QGEN stock has increased by 33.2% and is now trading at $54.76.
View which stocks have been most impacted by COVID-19

Are investors shorting QIAGEN?

QIAGEN saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 3,580,000 shares, a drop of 33.1% from the October 31st total of 5,350,000 shares. Based on an average daily trading volume, of 809,100 shares, the days-to-cover ratio is presently 4.4 days. Currently, 1.6% of the shares of the stock are sold short.
View QIAGEN's Short Interest

When is QIAGEN's next earnings date?

QIAGEN is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for QIAGEN

How were QIAGEN's earnings last quarter?

QIAGEN (NYSE:QGEN) announced its quarterly earnings data on Wednesday, November, 3rd. The company reported $0.58 EPS for the quarter, beating the consensus estimate of $0.53 by $0.05. QIAGEN had a net margin of 26.61% and a trailing twelve-month return on equity of 20.71%. During the same period in the previous year, the firm posted $0.58 EPS.
View QIAGEN's earnings history

What guidance has QIAGEN issued on next quarter's earnings?

QIAGEN updated its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided EPS guidance of $2.480-$ for the period, compared to the Thomson Reuters consensus EPS estimate of $2.120. The company issued revenue guidance of $2.15 B-, compared to the consensus revenue estimate of $1.86 billion.

What price target have analysts set for QGEN?

12 Wall Street analysts have issued 1-year price objectives for QIAGEN's shares. Their forecasts range from $49.00 to $58.00. On average, they expect QIAGEN's stock price to reach $52.13 in the next twelve months. This suggests that the stock has a possible downside of 4.8%.
View analysts' price targets for QIAGEN
or view top-rated stocks among Wall Street analysts.

Who are QIAGEN's key executives?

QIAGEN's management team includes the following people:
  • Thierry Bernard, Chief Executive Officer & Managing Director
  • Barthold Piening, Senior Vice President & Head-Global Operations
  • Roland Sackers, Chief Financial Officer & Managing Director
  • Stephany Foster, Senior Vice President & Head-Human Resources
  • John Gilardi, Vice President & Head-Investor Relations

What is Thierry Bernard's approval rating as QIAGEN's CEO?

33 employees have rated QIAGEN CEO Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among QIAGEN's employees.

What other stocks do shareholders of QIAGEN own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QIAGEN investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).

What is QIAGEN's stock symbol?

QIAGEN trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

Who are QIAGEN's major shareholders?

QIAGEN's stock is owned by a variety of institutional and retail investors. Top institutional investors include Massachusetts Financial Services Co. MA (9.00%), Capital World Investors (2.84%), BlackRock Inc. (2.66%), Wellington Management Group LLP (2.33%), FIL Ltd (1.65%) and Schroder Investment Management Group (1.59%).

Which institutional investors are selling QIAGEN stock?

QGEN stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Citigroup Inc., Credit Suisse AG, FIL Ltd, Compagnie Lombard Odier SCmA, Farallon Capital Management LLC, Invesco Ltd., and Eversept Partners LP.

Which institutional investors are buying QIAGEN stock?

QGEN stock was bought by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Arrowstreet Capital Limited Partnership, BlackRock Inc., Goldman Sachs Group Inc., Sycomore Asset Management, Massachusetts Financial Services Co. MA, Liontrust Investment Partners LLP, and Morgan Stanley.

How do I buy shares of QIAGEN?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is QIAGEN's stock price today?

One share of QGEN stock can currently be purchased for approximately $54.76.

How much money does QIAGEN make?

QIAGEN has a market capitalization of $12.48 billion and generates $1.87 billion in revenue each year. The company earns $359.19 million in net income (profit) each year or $2.56 on an earnings per share basis.

How many employees does QIAGEN have?

QIAGEN employs 5,610 workers across the globe.

What is QIAGEN's official website?

The official website for QIAGEN is www.qiagen.com.

Where are QIAGEN's headquarters?

QIAGEN is headquartered at HULSTERWEG 82, VENLO P7, 5912.

How can I contact QIAGEN?

QIAGEN's mailing address is HULSTERWEG 82, VENLO P7, 5912. The company can be reached via phone at (177) 355-6600, via email at [email protected], or via fax at 31-77-355-6658.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.